Frazier Lifesciences Acquisition Corporation
Status: Closed Deal
U=S+W/3
W=S@11.5
| IPO Proceeds, $M | $138.00M |
|---|---|
| IPO Date | Dec 9, 2020 |
| CEO | James N. Topper, M.D., Ph.D. |
| Left Lead | Credit Suisse |
| IPO Cash in Trust | 100.0% |
| SPAC Tenor | 24 months |
| IPO Sector | Healthcare ▶ |
| IPO Geography | Global |
| Target Company | NewAmsterdam Pharma |
| Deal Announced | Jul 25, 2022 |
| Deal Size, $M | $326.00M |
| Deal Sector | Healthcare |
| Deal Geography | Europe |
| SEC Filings |
www.sec.gov 
|
| Approval Vote | Nov 15, 2022 |
| Amendment Vote | TBD |
| Closing Date | Nov 22, 2022 |
Formerly FLAC
NAMS
NAMSW
| Price | $18.55 |
|---|---|
| Last closing price | $17.83 |
| H/L, today | $17.43 / $18.62 |
| H/L, 52-week | $5.63 / $32.87 |
| Volume, today | 424,048 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in to view structure, cap table, and calendar of events.